October 1, 2015
Resignation of Director
Genetic Signatures Limited announces the resignation of Mr Patrick Noland as a Non- executive Director of the company to take up his new position in the company as Executive Vice President, US Operations. On September 22, 2015 Genetic Signatures announced the appointment of Mr Patrick Noland to the full-time position of Executive Vice President of US Operations.
September 29, 2015
Change of registered office address
Genetic Signatures Limited (ASX: GSS) advises effective today the Company’s registered office details have changed to:
Level 12,
680 George Street, Sydney NSW 2000.
Ph: +61 2 8280 7100
September 28, 2015
Date of 2015 Annual General Meeting
Genetic Signatures Limited (ASX: GSS) advises that its 2015 Annual General Meeting will be held on Monday 9 November 2015.
September 24, 2015
GSS Non-Deal Roadshow – 2015 Full Final Year Results Presentation
This presentation provides an update on the 2015 Full Final Year Results.
GSS Non-Deal Roadshow – 2015 Full Final Year Results Presentation
September 22, 2015
Genetic Signatures launches North America Commercial Operations
- Key appointment to drive North America Market Entry
- Complements Global Strategy for Product Commercialisation
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced the appointment of Patrick Noland to Executive VP, US Operations.
“We are thrilled to bring Pat on board as we launch US commercial operations for our molecular diagnostics platform,” said Genetic Signatures’ Chief Executive Officer, John Melki, PhD. “Pat’s decades of experience in the commercialisation of advanced biological testing services are a perfect fit for our US strategy as we introduce our recently listed FDA solution to the market.”
Prior to joining Genetic Signatures, Mr. Noland was the CEO of StrataDX, an anatomic pathology laboratory based in Lexington, Massachusetts. Prior to his tenure at StrataDX, Mr. Noland spent 17 years in sales leadership roles at Laboratory Corporation of America® Holdings (LabCorp®, NYSE:LH), a clinical-laboratory company with over $5 billion in annual revenue. In his last role at LabCorp, Pat served as Senior Vice President responsible for developing and implementing a new partnerships-focused hospital strategy, designed to expand the available US market. He holds a MBA from Kennesaw State University in Georgia and a BSc from the University of Georgia in Athens.
September 15, 2015
Appointment to Board of Directors – Dr Tony Radford
Genetic Signatures Limited (ASX: GSS) is pleased to announce the appointment of Dr Tony Radford to the Board of Directors of the Company.
Tony Radford has a PhD from La Trobe University, and was a member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics. He later joined AMRAD in pharmaceutical research and was Head of Development in 2000 when he left to co-found the diagnostic company Cellestis Limited, which listed on the ASX in 2001. Establishing offices and operations in the USA, Europe and Japan, Cellestis developed QuantiFERON –TB Gold, the worldwide benchmark for diagnosis of tuberculosis infection. Dr Radford was CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011 for approximately $400 million.
August 27, 2015
GSS Amended Appendix 4E and Audited Financial Report 30 June 2015
August 13, 2015
Genetic Signatures expands into multiple European countries for its infectious disease detection products
- Further expansion for EasyScreen™ Pathogen Detection products
- Distribution deals signed for Ireland and Poland
- Agreements support Genetic Signatures’ strategy of global market penetration and increased market share
Molecular diagnostics company Genetic Signatures (ASX: GSS) has announced that it has signed distribution deals for Ireland and Poland, further expanding the market reach for its EasyScreen™ Products.
July 30, 2015
Quarterly Cash Flow & Activities Report – GSS Appendix 4C 30 June 2015
July 22, 2015
Genetic Signatures gains FDA Listing for EasyScreen™ Sample Processing Kit
- First regulatory step towards full product suite commercialisation in US
- Enables US sales of the kit to broad customer base
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced it has received a United States Food and Drug Administration (FDA) listing for it’s clinical sample concentrator, the EasyScreen™ Sample Processing Kit (SP001). The FDA listing means that the company can legally sell it’s EasyScreen™ Sample Processing Kit in the US, a first step in the further release of other EasyScreen™ products planned for US markets.
